Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NUVB 
Nuvation Bio Inc (NUVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: NUVB (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.17
1 Year Target Price $8.17
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 56.12% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.42B USD | Price to earnings Ratio - | 1Y Target Price 8.17 |
Price to earnings Ratio - | 1Y Target Price 8.17 | ||
Volume (30-day avg) 7 | Beta 1.49 | 52 Weeks Range 1.54 - 4.40 | Updated Date 10/23/2025 |
52 Weeks Range 1.54 - 4.40 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1315.72% |
Management Effectiveness
Return on Assets (TTM) 20.17% | Return on Equity (TTM) -44.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 719873798 | Price to Sales(TTM) 98.95 |
Enterprise Value 719873798 | Price to Sales(TTM) 98.95 | ||
Enterprise Value to Revenue 50.15 | Enterprise Value to EBITDA 2.23 | Shares Outstanding 341272722 | Shares Floating 231047778 |
Shares Outstanding 341272722 | Shares Floating 231047778 | ||
Percent Insiders 19.02 | Percent Institutions 66.78 |
Upturn AI SWOT
Nuvation Bio Inc
Company Overview
History and Background
Nuvation Bio Inc. was founded in 2018 by Dr. David Hung, focusing on developing innovative therapies for unmet medical needs in oncology. The company went public through a reverse merger with Panacea Acquisition Corp. in 2021.
Core Business Areas
- Oncology Drug Development: Focuses on discovering, developing, and commercializing therapeutic candidates for cancer treatment.
Leadership and Structure
Dr. David Hung is the founder and CEO. The company has a board of directors overseeing its strategic direction and management team responsible for daily operations.
Top Products and Market Share
Key Offerings
- NUV-868: A BDNF-mimetic small molecule designed to target the TrkB receptor. Currently in clinical trials for solid tumors. There are no revenues generated yet. Competitors include companies developing other TrkB inhibitors or alternative cancer therapies.
- NUV-121: An oral and selective CDK2/4/6 inhibitor. Currently in clinical trials for HR+/HER2- breast cancer. There are no revenues generated yet. Competitors include other CDK4/6 inhibitors such as palbociclib (Ibrance) from Pfizer and ribociclib (Kisqali) from Novartis.
Market Dynamics
Industry Overview
The oncology drug development market is highly competitive and rapidly evolving, driven by advancements in cancer biology and treatment modalities. There is strong demand for new and effective therapies, creating significant opportunities for innovative companies.
Positioning
Nuvation Bio aims to differentiate itself through its focus on novel targets and mechanisms of action in oncology. Its competitive advantage lies in its experienced management team and promising pipeline of drug candidates.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Nuvation Bio is targeting specific cancer subtypes, positioning itself to capture a portion of this large TAM.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Promising pipeline of drug candidates
- Focus on novel targets
- Strong financial backing
Weaknesses
- Early-stage drug development company
- High risk of clinical trial failures
- Dependence on key personnel
- No currently approved products
Opportunities
- Advancements in cancer biology
- Growing demand for personalized medicine
- Potential for strategic partnerships
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- PFE
- NVS
- MRTX
- ARRY
Competitive Landscape
Nuvation Bio faces significant competition from established pharmaceutical companies with greater resources and approved products. Its success hinges on demonstrating the efficacy and safety of its drug candidates and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is represented by progress in clinical trials and pipeline expansion.
Future Projections: Future growth is dependent on the success of its clinical trials and potential regulatory approvals. Analyst estimates are not available without real-time data sources.
Recent Initiatives: Recent initiatives include advancing NUV-868 and NUV-121 through clinical trials and exploring new therapeutic targets.
Summary
Nuvation Bio is a clinical-stage oncology company with a promising pipeline but faces substantial risks and competition. Its success depends on positive clinical trial results and regulatory approvals for its drug candidates. The company has a strong management team and financial backing, but its lack of revenue-generating products makes it a speculative investment. Investors should closely monitor the progress of its clinical trials and the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvation Bio Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2020-08-24 | Founder, President, CEO & Chairman Dr. David T. Hung M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 278 | Website https://www.nuvationbio.com |
Full time employees 278 | Website https://www.nuvationbio.com | ||
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.